These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22861670)

  • 1. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.
    Tomlin A; Reith D; Dovey S; Tilyard M
    Drug Saf; 2012 Sep; 35(9):733-43. PubMed ID: 22861670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis.
    Kunac DL; Tatley MV
    Drug Saf; 2011 Jan; 34(1):59-71. PubMed ID: 21142271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.
    Pariente A; Daveluy A; Laribière-Bénard A; Miremont-Salame G; Begaud B; Moore N
    Drug Saf; 2009; 32(5):441-7. PubMed ID: 19419238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine.
    Fisher S; Kent TA; Bryant SG
    J Clin Psychiatry; 1995 Jul; 56(7):288-96. PubMed ID: 7615482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients.
    Tomlin AM; Reith DM; Woods DJ; Lloyd HS; Smith A; Fountain JS; Tilyard MW
    Drug Saf; 2017 Dec; 40(12):1259-1277. PubMed ID: 28766108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reasons for Discontinuation or Change of Selective Serotonin Reuptake Inhibitors in Online Drug Reviews.
    Golder S; Medaglio D; O'Connor K; Hennessy S; Gross R; Gonzalez Hernandez G
    JAMA Netw Open; 2023 Jul; 6(7):e2323746. PubMed ID: 37459097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and guide to selection of selective serotonin reuptake inhibitors.
    Edwards JG; Anderson I
    Drugs; 1999 Apr; 57(4):507-33. PubMed ID: 10235690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse event reporting with selective serotonin-reuptake inhibitors.
    Hartnell NR; Wilson JP; Patel NC; Crismon ML
    Ann Pharmacother; 2003 Oct; 37(10):1387-91. PubMed ID: 14519041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database.
    Kim S; Park K; Kim MS; Yang BR; Choi HJ; Park BJ
    Psychiatry Res; 2017 Oct; 256():237-242. PubMed ID: 28646789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recording of adverse events in English general practice: analysis of data from electronic patient records.
    Tsang C; Majeed A; Banarsee R; Gnani S; Aylin P
    Inform Prim Care; 2010; 18(2):117-24. PubMed ID: 21078234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Care Medication Safety Surveillance with Integrated Primary and Secondary Care Electronic Health Records: A Cross-Sectional Study.
    Akbarov A; Kontopantelis E; Sperrin M; Stocks SJ; Williams R; Rodgers S; Avery A; Buchan I; Ashcroft DM
    Drug Saf; 2015 Jul; 38(7):671-82. PubMed ID: 26100143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.
    Coloma PM; Avillach P; Salvo F; Schuemie MJ; Ferrajolo C; Pariente A; Fourrier-Réglat A; Molokhia M; Patadia V; van der Lei J; Sturkenboom M; Trifirò G
    Drug Saf; 2013 Jan; 36(1):13-23. PubMed ID: 23315292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records.
    Abedian Kalkhoran H; Zwaveling J; van Hunsel F; Kant A
    J Med Syst; 2024 May; 48(1):51. PubMed ID: 38753223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective drug safety monitoring using the UK primary-care General Practice Research Database: theoretical framework, feasibility analysis and extrapolation to future scenarios.
    Johansson S; Wallander MA; de Abajo FJ; García Rodríguez LA
    Drug Saf; 2010 Mar; 33(3):223-32. PubMed ID: 20158286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of adverse events in patients receiving treatment for malaria in urban Ghana: a cohort-event monitoring study.
    Dodoo AN; Fogg C; Nartey ET; Ferreira GL; Adjei GO; Kudzi W; Sulley AM; Kodua A; Ofori-Adjei D
    Drug Saf; 2014 Jun; 37(6):433-48. PubMed ID: 24788801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.
    Buggy Y; Cornelius V; Fogg C; Kasliwal R; Layton D; Shakir SA
    Drug Saf; 2013 Jul; 36(7):521-31. PubMed ID: 23657823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
    Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
    J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
    Alvarez Y; Hidalgo A; Maignen F; Slattery J
    Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.